Christopher Lieu, MD, FASCO

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options based on patient needs and prior therapies.

Explore advanced treatment options for gastrointestinal neuroendocrine tumors, focusing on real-world case studies and emerging clinical data.